(0.32%) 5 116.46 points
(0.31%) 38 359 points
(0.36%) 15 985 points
(-0.88%) $83.11
(5.93%) $2.04
(0.39%) $2 356.40
(0.42%) $27.65
(3.90%) $958.05
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases...
Stats | |
---|---|
本日の出来高 | 1 018.00 |
平均出来高 | 19 953.00 |
時価総額 | 18.34M |
EPS | $0 ( 2024-04-05 ) |
次の収益日 | ( $-2.89 ) 2024-06-11 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.380 |
ATR14 | $0.114 (1.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Trachtenberg Eric | Buy | 4 600 | Common Stock |
2024-01-04 | Trachtenberg Eric | Sell | 1 227 | Common Stock |
2024-01-04 | Trachtenberg Eric | Buy | 20 500 | Stock Option (right to buy) |
2024-01-04 | Kharabi Darius | Buy | 4 600 | Common Stock |
2024-01-04 | Kharabi Darius | Sell | 1 385 | Common Stock |
INSIDER POWER |
---|
92.84 |
Last 100 transactions |
Buy: 1 301 269 | Sell: 48 062 |
Kala Pharmaceuticals Inc 相関
10 最も正の相関 | |
---|---|
EOLS | 0.852 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Kala Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-303 000 (0.00 %) |
EPS: | $-17.35 |
FY | 2023 |
収益: | $0 |
総利益: | $-303 000 (0.00 %) |
EPS: | $-17.35 |
FY | 2022 |
収益: | $3.89M |
総利益: | $1.33M (34.22 %) |
EPS: | $-0.150 |
FY | 2021 |
収益: | $11.24M |
総利益: | $7.14M (63.55 %) |
EPS: | $-136.13 |
Financial Reports:
No articles found.
Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。